Previously, cancer chemotherapy was often accompanied by severe side effects. Antibody drug conjugates (ADCs) were introduced to address this treatment complication. ADCs are a potent category of bioconjugates and immunoconjugates designed as targeted therapy for the treatment of cancer. ADCs are complex molecules composed of an antibody linked via linker chemistry to a cytotoxic payload or drug. Therefore, biologic properties of the cell‐surface target antigen are important in designing an effective ADC as an anticancer agent. ADCs have the ability to discriminate between the healthy and diseased tissue, so that healthy cells are less effected and get maximum therapeutic benefit. This review describes the development, characterization, and regulatory consideration of ADCs, and it summarizes the approved products in the market and in clinical trials.

中文翻译：

---

抗体药物偶联物：开发，表征和监管方面的考虑

以前，癌症化学疗法通常伴有严重的副作用。引入抗体药物偶联物（ADC）来解决这种治疗并发症。ADC是被设计为用于癌症治疗的靶向疗法的生物结合物和免疫结合物的有效类别。ADC是由抗体组成的复杂分子，这些抗体通过接头化学作用与细胞毒性有效载荷或药物连接。因此，细胞表面靶抗原的生物学特性对于设计有效的ADC作为抗癌剂非常重要。ADC具有区分健康组织和患病组织的能力，因此健康细胞受到的影响较小，并获得最大的治疗益处。这篇评论描述了ADC的开发，表征和监管方面的考虑，